PACS | Jotup

Amalgamated Financial Corp. Reports First Quarter 2024 Financial Results; Stellar Deposit Growth; Net Interest Margin Rises to 3.49%

Retrieved on:

Giovedì, Aprile 25, 2024

Common equity, Sale, Total, Investment, Capital, ICS, AMAL, One-Way (novel), Earnings call, Tax, PACE, CECL, Optimism, Eastern Time Zone, Share repurchase, Amalgamated Bank, PACS, GAAP, Bank

Net interest income was $68.0 million for the first quarter of 2024, compared to $67.3 million for the fourth quarter of 2023.

Key Points:

Net interest income was $68.0 million for the first quarter of 2024, compared to $67.3 million for the fourth quarter of 2023.
Net interest margin was 3.49% for the first quarter of 2024, an increase of 5 basis points from 3.44% in the fourth quarter of 2023.
Prepayment penalties had no impact on our net interest margin in the first quarter of 2024, which is the same as in the prior quarter.
As previously announced, Amalgamated Financial Corp. will host a conference call to discuss its first quarter 2024 results today, April 25, 2024 at 11:00am (Eastern Time).

Top 100 U.S. Hospital Health System Selects Intelerad to Deliver Enterprise Imaging Solution

Retrieved on:

Mercoledì, Aprile 24, 2024

Hospital, Partnership, Southeastern United States, Labour, Radiology, PACS, Face

Raleigh, North Carolina, April 24, 2024 (GLOBE NEWSWIRE) -- Intelerad Medical Systems™ , a global leader in medical imaging software solutions, today announced the successful go-live of its enterprise imaging solutions at a top 100 U.S. hospital health system.

Key Points:

Raleigh, North Carolina, April 24, 2024 (GLOBE NEWSWIRE) -- Intelerad Medical Systems™ , a global leader in medical imaging software solutions, today announced the successful go-live of its enterprise imaging solutions at a top 100 U.S. hospital health system.
The implementation is Intelerad’s second recent go-live for a major health system , most notably signing a multi-year contract with a top 50 U.S. hospital in Michigan.
"Intelerad’s strength lies in our ability to scale and innovate in response to the ever-evolving needs of the healthcare sector," said Intelerad CEO Jordan Bazinsky .
The collaboration’s timing coincides with a critical period in the healthcare industry, as providers continue to face financial strain, burnout, and staff shortages.

iCAD Showcases New ProFound Cloud, Enhanced ProFound Detection Workstation Features and New Strategic Partnerships at SBI Annual Symposium

Retrieved on:

Giovedì, Aprile 11, 2024

Cloud, Society, Cancer, ICAD, Radiology, Health equity, Mammography, AI, Google Cloud, SBI, Partnership, Symposium, 3D, PACS, Patient, 2D, Breast cancer, Architecture, Medical imaging

In addition, iCAD will feature its recent release of the ProFound Detection Workstation features for streamlined mammogram interpretations in booth #512.

Key Points:

In addition, iCAD will feature its recent release of the ProFound Detection Workstation features for streamlined mammogram interpretations in booth #512.
“We’re excited to highlight our recent notable advancements at the SBI annual symposium this year,” said Dana Brown, President and CEO of iCAD.
Visitors to the iCAD booth will also be able to witness the new advanced workstation features for ProFound Detection for both 2D and 3D mammography in its latest V3 Service Pack update.
Symposium attendees are invited to visit iCAD’s booth #512 or schedule a meeting at https://www.icadmed.com/about/news-events/upcoming-tradeshows-and-meetin... to discuss iCAD’s newest partnerships and product demonstrations.

Crucial Data Solutions Introduces TrialKit PACS to Streamline Image Management in Clinical Trials

Retrieved on:

Martedì, Aprile 23, 2024

Crucial Data Solutions (CDS), a leading provider of data collection and trial management software to advance clinical research, today announced the launch of TrialKit PACS .

Key Points:

Crucial Data Solutions (CDS), a leading provider of data collection and trial management software to advance clinical research, today announced the launch of TrialKit PACS .
This innovative solution streamlines medical image management within clinical trials, offering a unified platform for all data collection and management needs.
TrialKit PACS streamlines medical image capture into EDC trials by eliminating the time and cost of third party systems licensing and integration.
Founded in 2010, Crucial Data Solutions (CDS) provides the most innovative data collection and clinical trial management technology on the market today.

PACS Group, Inc. Announces Closing of Its Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares from the Selling Stockholders

Retrieved on:

Martedì, Aprile 16, 2024

In addition, the underwriters have exercised their 30-day option to purchase an additional 3,214,284 shares of the Company’s common stock at the initial public offering price from the selling stockholders, less underwriting discounts and commissions.

Key Points:

In addition, the underwriters have exercised their 30-day option to purchase an additional 3,214,284 shares of the Company’s common stock at the initial public offering price from the selling stockholders, less underwriting discounts and commissions.
PACS did not receive any proceeds from any sale of shares by the selling stockholders.
The Company’s common stock is listed on the New York Stock Exchange under the ticker symbol “PACS.”
This press release features multimedia.
(Photo: NYSE Group, Inc.)
Citigroup, J.P. Morgan and Truist Securities acted as lead book-running managers for the offering.

Gathid Sets New Identity and Access Governance Standard with Introduction of Patented Identity Model

Retrieved on:

Mercoledì, Aprile 10, 2024

Data Management, Security, Technology, Software, Networks, Internet, ROI, KPMG, AISA, UAR, ASX, GTH, Automation, PACS, RBAC, IAM, Kiosk, Sod, Data analysis, Memory, Algorithm, Organization, Online shopping

Inspired by the power of gathered identities, the platform pinpoints identity and access anomalies with its patented directed graph model.

Key Points:

Inspired by the power of gathered identities, the platform pinpoints identity and access anomalies with its patented directed graph model.
In Q4 2023, Gathid successfully transitioned from physical security to identity governance to address this gap.
Identity graph technology: Gathid’s patented approach constructs a daily identity graph model, enabling the representation of virtual data relationships between identities and access rights to systems.
The Gathid Graph does not attempt to maintain concurrency of its identity model; it simply receives daily snapshots and rebuilds the identity and access model, archiving the previous model when a new model is created from fresh data.

PACS Group, Inc. Announces Pricing of Its Upsized Initial Public Offering

Retrieved on:

Giovedì, Aprile 11, 2024

PACS Group, Inc. (“PACS” or the “Company”) today announced the pricing of its upsized initial public offering of 21,428,572 shares of its common stock being sold by the Company at a public offering price of $21.00 per share, for total gross proceeds of approximately $450 million, before deducting underwriting discounts and commissions and offering expenses.

Key Points:

PACS Group, Inc. (“PACS” or the “Company”) today announced the pricing of its upsized initial public offering of 21,428,572 shares of its common stock being sold by the Company at a public offering price of $21.00 per share, for total gross proceeds of approximately $450 million, before deducting underwriting discounts and commissions and offering expenses.
In addition, certain selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 3,214,284 shares of the Company’s common stock at the initial public offering price, less underwriting discounts and commissions.
PACS will not receive any proceeds from any sale of shares by the selling stockholders.
Citigroup, J.P. Morgan and Truist Securities are acting as lead book-running managers for the offering.

DFI Revolutionizes Industrial Computing with World's First MicroATX Motherboards

Retrieved on:

Giovedì, Aprile 11, 2024

Magnetic resonance imaging, PCI Express, X-ray, DFI, PACS, Intel Core, Medicine, Diagnosis, GPU, Automation, Medical imaging

TAIPEI, April 11, 2024 /PRNewswire/ -- DFI, the world's leading brand in embedded motherboards and industrial computers, is thrilled to announce two of the world's first Industrial MicroATX motherboards to support Intel® Core™ 12th, 13th, and 14th (Alder Lake-S, Raptor Lake-S and Raptor Lake-S Refresh) Gen Processors. "With support for the latest Intel Core processors and features including dual GPU slots and dual 10GbE ports, RPS310 and ADS310 represent a significant leap forward in innovation for industrial and medical computing, empowering manufacturing and healthcare professionals to achieve new levels of efficiency," said Jarry Chang, General Manager of Products Center at DFI.

Key Points:

TAIPEI, April 11, 2024 /PRNewswire/ -- DFI , the world's leading brand in embedded motherboards and industrial computers, is thrilled to announce two of the world's first Industrial MicroATX motherboards to support Intel® Core™ 12th, 13th, and 14th (Alder Lake-S, Raptor Lake-S and Raptor Lake-S Refresh) Gen Processors.
In medical settings, the dual 10GbE ports of the ADS310 offer lightning-fast network connectivity and accelerated data transfer speeds, providing crucial advantages to healthcare professionals.
These ports enable quick access to large medical imaging files and improved transfer speeds between PACS servers, accelerating diagnosis and treatment processes.
Similarly, in factory automation, they ensure rapid data transfer between machines, enhancing monitoring and response capabilities.

Xlife Sciences AG Announces Collaboration Agreement Between its Portfolio Company FUSE-AI GmbH and T-Systems Switzerland

Retrieved on:

Mercoledì, Aprile 10, 2024

Cloud, European Economic Area, MRI, CE, Partnership, Research, Science, Radiology, AI, Software, T-Systems, EEA, MDR, PACS, BSI Group, Health, BSI, Medical device

Xlife Sciences is pleased to announce a collaboration between its portfolio company, FUSE-AI, and T-Systems Switzerland.

Key Points:

Xlife Sciences is pleased to announce a collaboration between its portfolio company, FUSE-AI, and T-Systems Switzerland.
T-Systems Switzerland, as a subsidiary of T-Systems International GmbH, is considered a system-relevant IT and digitalization partner in the healthcare sector in Switzerland.
Through this cooperation, T-Systems Switzerland distributes the AI-based solution for prostate analysis from FUSE-AI centrally in Switzerland, thereby enabling the commercialization of «Prostate.Carcinoma.ai» for radiological clinics and practices.
Xlife Sciences sees this partnership as a significant contribution to continuing its mission to bridge the gap between innovations and the needs of the healthcare market.

Online Platform Reveals Massive Political Contributions to 2024 Candidates

Retrieved on:

Mercoledì, Aprile 3, 2024

House, Organization, IPhone, Coral Gables, Florida, FEC, PACS, Legislation, Government, Senate, Representative, Android

MOXY voter empowerment platform now includes explicit details on campaign fundraising

Key Points:

Coral Gables, Florida--(Newsfile Corp. - April 3, 2024) - Epluribus LLC, creators of MOXY™, announced in-depth reporting on campaign contributions to U.S. Congressional and Presidential campaigns within its just-released 4.0 app and website platform.
Contributions in the 2020 national election cycle skyrocketed to nearly $8 billion yet the 2024 cycle appears on the track to demolish that record.
The funds reaped from large individual donors and organizations, such as wealthy individuals and political action committees (PACs), far outweigh the contributions made by small individual donors by a factor of 3-times.
Due to the expense of running a campaign, candidates for public office must solicit contributions across the spectrum but more quickly reach their fundraising goals by targeting special interest groups and deep-pocketed donors.